ChadLDealMD

PubMed

• 1 citations
  Improvement in quality of life after asfotase alfa treatment in adults with pediatric-onset hypophosphatasia: data from 5 patient-reported outcome measures.
  Kathryn M Dahir, Steven W Ing, Chad Deal, Andrew Messali, Toby Bates
  JBMR Plus. 2024-08-01
• Treatment patterns in women with postmenopausal osteoporosis using abaloparatide: a real-world observational study.
  Deborah T Gold, Tammy Beckett, Chad Deal, Andrew L James, Mahshid Mohseni
  Osteoporosis International. 2024-08-01
• Correction: Hypophosphatasia diagnosis: current state of the art and proposed diagnostic criteria for children and adults.
  Aliya A Khan, Maria Luisa Brandi, Eric T Rush, Dalal S Ali, Hatim Al-Alwani
  Osteoporosis International. 2024-05-01

Journal Articles

• Left clavicular fracture  
  He L, Winalski CS, Deal C, Holden D, Skeletal Radiol, 1/1/2016
• DXA utilization between 2006 and 2012 in commercially insured younger postmenopausal women  
  Overman RA, Farley JF, Curtis JR, Zhang J, Gourlay ML, Deal CL, J Clin Densitometry, 1/1/2015
• Fracture rate associated with quality metric-based anti-osteoporosis treatment in glucocorticoid-induced osteoporosis  
  Overman RA, Gourlay ML, Deal CL, Farley JF, Brookhart MA, Layton JB., Osteoporos Int., 1/1/2015
• United States adults meeting 2010 American College of Rheumatology criteria for treatment and prevention of glucocorticoid-induced osteoporosis  
  Overman R, Toliver JC, Gourlay ML, Deal CL, Arthritis Rheumatol, 1/1/2014
• The Regional Distribution of Rheumatologists: What Can We Do, What Should We Do  
  Deal C, Arthritis Rheum, 1/1/2013
• Indications of DXA in Women Younger than 65 yr and Men Younger than 70 yr  
  Malabanan A, Rosen H, Vokes T, Deal C, et al., The 2013 Official Positions, 1/1/2013
• The official positions of the International Society for Clinical Densitometry: Vertebral Fracture Assessment  
  Rosen H, Vokes T, Malabanan A, Deal C, et al., J Clin Densitom, 1/1/2013
• Prevalence of oral glucocorticoid usage in the United States: A general population perspective  
  Overman RA, Jun-Yen Y, Deal C, Arthritis Care Res, 1/1/2013
• Recent recommendations on steroid-induced osteoporosis: More targeted, but more complicated  
  Deal C, Clev Clinic J Med, 1/1/2013
• Bone Loss in rheumatoid arthritis: Systemic, periarticular and focal  
  Deal C, Curr Rheumatol Rep, 1/1/2012
• Emerging therapies for osteoporosis  
  Deal C, Rheum Dis Clin N Am, 1/1/2011
• American College of Rheumatology 2010 Recommendations for the Prevention and Treatment of Glucocorticoid-Induced Osteoporosis  
  Grossman J, Gordon R, Ranganath VK, Deal C, et al., Arthritis Care Res, 1/1/2010
• A 21-year-old man with Still’s Disease with fever, rash and pancytopenia  
  Mehta B, Hashkes P, Avery R, Deal C, Arthritis Care Res, 1/1/2010
• Comparison of the effect of denosumab and alendronate on BMD and biochemical markers of bone turnover in postmenopausal women with low bone mass: A randomized blinded,...  
  Brown J, Prince R, Deal C, et al., J Bone Miner Res, 1/1/2009
• Potential new drug targets for osteoporosis  
  Deal C, Nature Clinical Practice Rheumatology, 1/1/2009
• Absolute fracture risk  
  Deal C, Current Rheumatology Reports, 1/1/2007
• Combination therapy with antiresorptive and anabolic agents  
  Deal C, Clinical Reviews in Bone and Mineral Metabolism, 1/1/2006
• Combination therapy: rethinking the paradigm  
  Deal C, Osteoporosis Today, 1/1/2006
• Secondary osteoporosis: are we recognizing it?  
  Sikon A, Thacker H, Carey J, Deal C, Licata A, Journal Women’s Health, 1/1/2006
• Successes and failures in improving osteoporosis care after fragility fracture : results of a multi-site clinical improvement project  
  Harrington T, Deal C, Arthritis Rheum (Arthritis Care & Research), 1/1/2006
• Raloxifene: a selective estrogen-receptor modulator for postmenopausal osteoporosis - a clinical update on efficacy and safety  
  Deal C, Draper MW, Women’s Health, 1/1/2006
• Osteoporosis therapies: Bisphosphonates, SERMs, PTH, and new therapies  
  Deal CL, Clinical Reviews in Bone and Mineral Metabolism, 1/1/2005
• Clinical use of teriparatide in the real world: Initial insights  
  Miller PD, Bilezikian JP, Deal C, et al., Endocrine Practice, 1/1/2004
• Glucocorticocoids and fracture risk  
  Deal CL, Osteoporosis Today, 1/1/2004
• The use of intermittent human parathyroid hormone as a treatment for osteoporosis  
  Deal CL, Current Rheumatology Reports, 1/1/2004
• Join now to see all

Books/Book Chapters

• Rheumatology 
  Chapter: Chapter 201: Management of Osteoporosis 
  Deal C, Abelson AEditors: Hochberg M, et al.Mosby2014
• Rheumatology 
  Chapter: Chapter 190: Management of Osteoporosis 
  Deal C, Abelson A, CareyEditors: Hochberg M, et al.Mosby2007
• Bone Disease in Rheumatology 
  Chapter: Use of bisphosphonates in rheumatic disease and osteoporosis 
  Deal CLEditors: Gluck O, Maricic M.Lippincott, Williams and Wilkins2005
• Current Geriatric Diagnosis and Treatment 
  Chapter: Osteoporosis and hip fractures 
  Srivastava M, Deal CEditors: Palmer R.Lange Medical Books2004
• Diagnostic Procedures Handbook 
  Chapter: Bone density 
  Deal CLEditors: Michota FA.Lexi-Comp, Inc., Hudson, OH2001
• Neuromuscular Disorders in Clinical Practice 
  Chapter: Chapter 85: Polymyalgia Rheumatica 
  Deal CLEditors: Katirji B, et al.Butterworth Heinemann, Boston2001
• Serving Minority Elders in the 21st Century 
  Chapter: Osteoporosis Overview--Should minorities be concerned? 
  Deal CLEditors: Wykle ML, Ford AB.Springer, New York, N.Y.1999
• Oxford Textbook of Rheumatology 
  Chapter: Endocrinology in the rheumatic diseases 
  Deal CLEditors: Maddison PJ, et al.Oxford University Press1993
• Clinical Problems in Acute Care Medicine 
  Chapter: Acute presentations of common rheumatic problems, anaphylaxis, angioedema 
  Deal CLEditors: Hefferman JJ, Witzburg RA, Cohen AS.W.B. Saunders Company1989
• C-reactive Protein and the Plasma Protein Response to Tissue Injury 
  Chapter: The effect of amyloid enhancing factor (AEF) on the acute phase serum amyloid A (SAA) and serum amyloid P (SAP) response to silver nitrate 
  Deal CL, Sipe JD, Skinner M, Tatsuta E, Cohen ASEditors: Kushner I, Volanakis JE Gerwurz H.New York Academy of Sciences, New York1982
• Join now to see all

Abstracts/Posters

• Health Utility following osteoporotic fracture using SF6D: Results form ICUROS US
  Silverman S, Gold DT, Schousboe JT, Deal CL, et al., J Bone Miner Res, 1/1/2015
• Adherence to denosumab in a large healthcare system
  Overman RA, Lauffenburger JC, Gourlay ML, Deal CL, Arthritis Rheumatol, 1/1/2014
• Continued zoledronic acid use in a large healthcare system
  Overman RA, Lauffenburger JC, Gourlay ML, Deal CL, Arthritis Rheumatol, 1/1/2014
• Anti-Osteoporosis medication use after hip or vertebral fracture
  Overman RA, Deal CL, Arthritis Rheumatol, 1/1/2014
• Evaluation of osteoporosis starts in patients based on T-score and FRAX® absolute fracture risk model in a large health care system
  Overman R, Deal C, Arthritis and Rheumatism, 1/1/2013
• Proportion of US older adults meeting inclusion criteria for 2010 ACR Recommendations on Glucocorticoid-Induced-Osteoporosis
  Overman R, Toliver J, Yeh JY, Gourlay M, Deal C, Arthritis and Rheumatism, 1/1/2013
• Use of Uric Lowering Therapies within a Large Health Care System
  Overman, R, Deal, C, Mandell B, Arthritis & Rheumatism, 1/1/2012
• Treatment of bacterial overgrowth and vitamin D levels
  Williams S, Licata A, Deal C, Endocrine Reviews, 1/1/2010
• Effect of denosumab vs alendronate on bone turnover markers and bone density changes at 12 months based on baseline bone turnover level
  Brown J, Deal C, Gregorio LH, Hofbauer LC, Wang H, Austin M, Wagman RB, Newmark R, Libanati C, San Martin J, J Bone Miner Res, 1/1/2008
• Zoledronic acid prevents accelerated bone loss after discontinuation of teriparatide
  Deal C, Tuthill K, Kreigman A, J Bone Miner Res, 1/1/2008
• BMD response to teriparatide in patients previously treated with a bisphosphonate versus treatment naïve patients
  File EA, Deal C, Arthritis Rheum, 1/1/2007
• Characteristics of rheumatology practices that employ physician assistants and nurse practitioners : Findings of the American College of Rheumatology subcommittee on w...
  Hooker R, Deal C, Barr W, et al., Arthritis Rheum, 1/1/2006
• US rheumatology supply and demand : 2005-2006 workforce study
  Deal C, Barr W, Harrington T, et al., Arthritis Rheum, 1/1/2006
• Adult hypophosphatasia treated with Teriparatide
  Deal C, Whyte MP, J Bone Min Res, 1/1/2005
• Outcome after formal recommendation to evaluate for secondary causes of low bone mass on the bone mineral density report
  Carey J, Delaney M, Licata A, Deal C, et al., Arthritis Rheum, 1/1/2005
• Raloxifene in combination with teriparatide reduces teriparatide-induced stimulation of bone resorption but not formation in postmentopausal women with osteoporosis
  Deal C, Omizo M, Schwartz E, et al., J Bone Min Res, 1/1/2004
• Concomitant teriparatide plus raloxifene for the treatment of postmenopausal osteoporosis: results from a randomized placebo-controlled trial
  Deal C, Omizo M, Schwartz E, et al., Arthritis Rheum, 1/1/2004
• Calcaneal ultrasound-influence of activity and comparison with standard Dexa measurements in general clinical practice
  Danese RD, Licata AP, Richmond B, Deal C, Osteoporosis Int, 1/1/2000
• A psychosocial program to decrease the risk of osteoporosis
  Kwoh CK, Deal CL, Moskowitz RW, Arthritis Rheum, 1/1/1998
• Treatment of osteoarthritis of the knee with pulsed electrical stimulation
  Deal CL, Zizic TM. Hoffman TC, Holt PA, Hungerford TS, Arthritis Rheum, 1/1/1993
• Factors influencing vertebral bone density after renal transplantation
  Wolpaw TM, Deal CL, Schulak JA, Hricik DE, J Am Soc Nephrol, 1/1/1993
• Changes in total body composition with high dose corticosteroids
  Deal CL, Eberle RW, Mazess RB, Barden H, Arthritis Rheum, 1/1/1992
• Bone loss in patients treated with high dose corticosteroids
  Deal CL, Eberle RW, Mazess RB, Barden H, Arthritis Rheum, 1/1/1992
• Changes in bone and body composition with high dose corticosteroids over three months
  Deal CL, Eberle RW, Mazess RB, Barden H, Journal of Bone and Mineral Research, 1/1/1992
• DEXA measurement of peri-prosthetic bone mineral density in total hip arthroplasty
  Richmond BJ, Eberle RW, Stulberg BN, Deal CL, 8th International Workshop on Bone Densitometry, Bad Reichenhall, Germany, 1/29/1991
• Join now to see all

Lectures

• Essentials for the Spine Care Clinician 
  Cleveland Clinic - Cleveland, Ohio / The Cleveland Clinic Foundation, Cleveland, Ohio - 11/3/2012
• Nephrology Update 2012 
  Cleveland Clinic - Cleveland, Ohio / The Cleveland Clinic Foundation, Cleveland, Ohio - 9/27/2012